AstraZeneca, breast cancer
AstraZeneca’s Datroway approved in U.S. for HER2-negative breast cancer patients
DXd, has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.
AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for 50% of the company’s total revenue by 2030.
AstraZeneca has overhauled its local management in China, replacing Michael Lai with Alex Lin as the country's general ...
AstraZeneca restructures its China operations following leadership scandals and sales challenges, appointing new executives ...
From accelerating drug development and clinical trials to supercharging collaboration, machine learning-enhanced healthcare ...
It’s a sobering statistic: 1 in 8 women in the United States will be diagnosed with breast cancer during her lifetime.1 ...
News Medical on MSN2d
AstraZeneca's Pioneering Research in Heart Failure and ATTR-CM: An interview with Mina MakerMina Makar highlights AstraZeneca's commitment to advancing heart failure research and innovative therapies, addressing ...
AstraZeneca’s share price has fallen a long way from its record-breaking level last year, which indicates that I may be ...
Shares of AstraZeneca PLC AZN rallied 1.84% to £108.44 Thursday, on what proved to be an all-around positive trading session ...
Guggenheim raised the firm’s price target on AstraZeneca (AZN) to 13,100 GBp from 12,600 GBp and keeps a Buy rating on the shares. The firm is ...
AstraZeneca’s Fasenra, an IL-5-targeting monoclonal antibody already approved for asthma, represents a promising contender ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback